EGFR and colorectal carcinoma: For example, a negative result could be interpretated as (i) the absence of a mutation indicating that the patient should receive anti-EGFR antibody therapy (in the case of CRC and RAS mutations) or that (ii) the patient would be unlikely to benefit from EGFR-tyrosine kinase Inhibitors (in the case of NSCLC and EGFR mutation).